(Q33752794)

29 July 2017

1 reference

title

The use of insulin alone and in combination with oral agents in type 2 diabetes (English)

1 reference

29 July 2017

1 reference

Buse JB

1

1 reference

PubMed ID

10523468

29 July 2017

language of work or name

1 reference

1 December 1999

1 reference

Primary Care: Clinics in Office Practice

29 July 2017

1 reference

29 July 2017

26

1 reference

29 July 2017

4

1 reference

29 July 2017

931-950

1 reference

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Management of glycemia in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

The insulin-sparing effect of metformin in insulin-treated diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Insulin plus a Sulfonylurea Agent for Treating Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Comparison of combined therapies in treatment of secondary failure to glyburide

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970140-8

7 January 2021

10.1016/S0095-4543(05)70140-8

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10523468